Related Experiment Video
Updated: Mar 24, 2026
Generation of a Novel Dendritic-cell Vaccine Using Melanoma and Squamous Cancer Stem Cells
Published on: January 6, 2014
Adjuvant-Loaded Subcellular Vesicles Derived From Disrupted Cancer Cells for Cancer Vaccination
Alexander S Cheung1,2, Sandeep T Koshy1,2,3, Alexander G Stafford2
1John A. Paulson School of Engineering and Applied Sciences, Harvard University, Cambridge, MA, 02138, USA.
Abstract:
Targeted subunit vaccines for cancer immunotherapy do not capture tumor antigenic complexity, and approaches employing tumor lysate are often limited by inefficient antigen uptake and presentation, and low immunogenicity. Here, whole cancer cells are processed to generate antigen-rich, membrane-enclosed subcellular particles, termed "reduced cancer cells", that reflect the diversity and breadth of the parent cancer cell antigen repertoire, and can be loaded with disparate adjuvant payloads. These vesicular particles enhance the uptake of the adjuvant payload, and potentiate the activation of primary dendritic cells in vitro. Similarly, reduced cancer cell-associated antigens are more efficiently presented by primary dendritic cells in vitro than their soluble counterparts or lysate control. In mice, vaccination using adjuvant-loaded reduced cancer cells facilitates the induction of antigen-specific cellular and humoral immune responses. Taken together, these observations demonstrate that adjuvant-loaded reduced cancer cells could be utilized in cancer vaccines as an alternative to lysate.
Insights
New "reduced cancer cells" offer a promising approach for cancer immunotherapy vaccines. These particles effectively present tumor antigens and adjuvants, enhancing immune responses compared to traditional methods.
Area of Science:
- Immunology
- Oncology
- Biotechnology
Background:
- Current cancer immunotherapies, such as subunit vaccines, often fail to address tumor antigenic complexity.
- Tumor lysate-based approaches face challenges with inefficient antigen uptake, presentation, and low immunogenicity.
Purpose of the Study:
- To develop a novel cancer vaccine platform using whole cancer cells processed into subcellular particles.
- To evaluate the efficacy of these particles in enhancing antigen presentation and immune response.
Main Methods:
- Whole cancer cells were processed into membrane-enclosed "reduced cancer cells" (RCCs) retaining antigen diversity.
- RCCs were loaded with adjuvant payloads and tested for dendritic cell activation and antigen presentation in vitro.
- Vaccination efficacy was assessed in mice using adjuvant-loaded RCCs.
Main Results:
- Reduced cancer cells effectively captured the parent cancer cell antigen repertoire.
- Vesicular particles enhanced adjuvant payload uptake and dendritic cell activation.
- RCC-associated antigens demonstrated superior presentation by dendritic cells compared to soluble antigens or lysate.
- Vaccination with adjuvant-loaded RCCs induced robust antigen-specific cellular and humoral immune responses in mice.
Conclusions:
- Adjuvant-loaded reduced cancer cells represent a viable alternative to tumor lysate in cancer vaccine development.
- This platform offers a strategy to overcome limitations of current cancer immunotherapy approaches by presenting a broad antigenic repertoire.
More Related Videos
Related Concept Videos
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
01:27Tumor Immunotherapy
01:51Vaccinations
01:35Cancer Cell Migration through Invadopodia
02:53Adaptive Mechanisms in Cancer Cells
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
02:53Adaptive Mechanisms in Cancer Cells